Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98 per share from the same period last year.